Showing 581-590 of 6036 results for "".
B+L Bolsters Glaucoma Offerings with Elios Acquisition
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-bolsters-glaucoma-offerings-with-elios-acquisition/37063/Bausch + Lomb makes an acquisition to expand its glaucoma offerings; Roche gets a major approval in Europe for Vabysmo; and EssilorLuxottica buys a maker of noninvasive ophthalmic medical devices. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhase 3 Results for Novel Sedation Tablet
https://modernod.com/podcasts/eyewire-news-the-podcast/phase-3-results-for-novel-sedation-tablet/37062/New phase 3 data is released for a non-opioid sedation tablet; the first patient is dosed in the phase 3 trial of EyePoint’s wet AMD candidate; and Outlook receives a reimbursement decision in the UK for its wet AMD treatment. Learn more about your ad choices. Visit megaphone.fm/adchoicesPhakic IOL for Presbyopia Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/phakic-iol-for-presbyopia-approved-in-europe/37061/A new phakic IOL for presbyopia is approved in Europe; Nidek launches its preloaded Toric IOL Injection System internationally; and the FDA cleared a novel device for the treatment of Meibomian Gland Dysfunction. Learn more about your ad choices. Visit megaphone.fm/adchoicesLLLT and AMD: Your Questions Answered
https://modernod.com/topics/retina/lllt-and-amd-your-questions-answered/37350/Joseph J. Allen, OD, FAAO, Dipl ABO, gives an overview of a recently FDA-authorized low-level light therapy, or photobiomodulation, device, the Valeda Light Delivery System (LumiThera). He explains the device’s unique mechanism of action for treating age-related macular degeneration, reviews promisiLumithera CEO Discusses FDA Authorization for Veleda for Dry AMD
https://modernod.com/podcasts/eyewire-news-the-podcast/lumithera-ceo-discusses-fda-authorization-for-veleda-for-dry-amd/37059/The CEO of Lumithera joins us to discuss the FDA authorization of the Veleda system for dry AMD; the FDA accepts the resubmitted NDA for dry eye disease candidate reproxalap; and Alcon launches the first contact lens designed for a 1-week replacement cycle.Successful Management of Vitreous Opacities
https://modernod.com/podcasts/the-mod-pod/successful-management-of-vitreous-opacities-2/36859/Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past decade. In this podcast, optometric thought leader Alison Bozung, OD, is joined by an esteemed panel of retina surgeons to discuss why more rVision Correction Guidelines for Patients Approaching Presbyopia
https://modernod.com/topics/contact-lenses/vision-correction-guidelines-for-patients-approaching-presbyopia/38781/Boost your multifocal contact lens fitting rates with effective patient engagement.Unraveling the Role of Accessory Lacrimal Glands
https://modernod.com/topics/ocular-surface/unraveling-the-role-of-accessory-lacrimal-glands/38766/Learn about the big effect these small glands have on dry eye dynamics.When Lashes Harbor Invaders
https://modernod.com/topics/ocular-surface/when-lashes-harbor-invaders/38676/Demodex case files offer pointers for improving patient outcomes.An Intro to the Latest Dry Eye Drop
https://modernod.com/podcasts/to-the-point/an-intro-to-the-latest-dry-eye-drop/36925/Get an overview of the recently FDA-approved perfluorohexyloctane ophthalmic solution (Miebo, Bausch + Lomb) from Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO. Drs. O’Dell and Garlich discuss the drop’s mechanism of action, dosing regimen, clinical trial findings, side effect profile, and m